Special Issue

Drug Candidates for Gastric Cancer

Message from the Guest Editors

Our understanding of the biology of gastric cancer (GC) has substantially improved over the last decade, leading to advances in targeted therapies and novel therapeutic approaches. Recent breakthroughs in potential therapeutic candidates for GC, as well as innovations in neoadiuvant and adjuvant chemotherapy. immunotherapy, and radiation treatment for GC, will be discussed in this Special Issue. This Special Issue will also discuss the roles of emerging therapeutics in both clinical and investigational fields, such as rational and structure-based drug design, which have the potential to improve the clinical outcome of these illnesses. Reviews and research papers are both welcome. Regarding GC, potential topics include, but are not limited to, the following: experimental therapeutics, drug candidates, drug repurposing, drug target discovery, drug screening, artificial intelligence in drug discovery, computational methods for drug repurposing and drug design, molecular dynamics, and molecular docking.

Guest Editors

Dr. Seungyoon Nam

Al Convergence Center for Medical Science, Department of Genome Medicine and Science, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon 21565, Korea

Dr. Jinhyuk Lee

Korea Research Institute of Bioscience and Biotechnology, Korean Bioinformation Center (KOBIC), Daejeon 305-806, Korea

Deadline for manuscript submissions

closed (23 February 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/119623

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

